Senseonics Holdings, Inc. · NASDAQ:SENS
Senseonics — Investor Day (September 2020)
24 slides from Senseonics's investor day presentation, Sep 15, 2020
Slide 1: Analyst & Investor Event
confidently live life with ease Analyst & Investor Event September 15, 2020
Slide 2: Cautionary Note Regarding Forward-looking Statements
Cautionary Note Regarding Forward-looking Statements This presentation contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding managements plans, objectives and goals for future operations, including preliminary targets
Slide 3: Analyst and Investor Event
Analyst and Investor Event Virtual event September 15, 2020 4:30 Tim Goodnow CEO Corporate strategy, operations and product roadmap 4:40 Robert Schumm President, Ascensia Worldwide distribution initiatives 4:50 Francine Kaufman, MD CMO Clinical integration of Eversense implantable CGM technology 5:0
Slide 4: Senseonics and Ascensia Diabetes Care
Senseonics and Ascensia Diabetes Care • Commercial Integration – Initiated August 10th 2020 – Initiate Eversense Commercial activities • U.S. by 10/1/20 • O.U.S. by 2/1/21 – Positive coverage progress (~ 80%) • Commercial payers • Medicare – Minimum 5-year Global Commercialization Agreement • Senseo
Slide 5: Senseonics and Ascensia Diabetes Care
Senseonics and Ascensia Diabetes Care • Economic Considerations – Revenue split, tiered & changes with installed base (mid-teens to mid-forties) – Senseonics Investment • Manufacturing & Product Development – Ascensia Diabetes Care Investment • Dedicated Commercial Staff & Infrastructure • Sales Rep
Slide 6: Senseonics Business Model
Senseonics Business Model • Senseonics Model Economics – Annual Revenue Target – Margin – Cash utilization – Breakeven
Slide 7: Senseonics Product Development
Senseonics Product Development • U.S. – 180 Day Sensor – FDA Submission • Performance • Reduced Calibration • Timeline
Slide 8: Introducing Ascensia Diabetes Care
Introducing Ascensia Diabetes Care Rob Schumm, President September 15, 2020 Company Confidential
Slide 9: Introducing Ascensia Diabetes Care
Introducing Ascensia Diabetes Care A LEADER in blood glucose monitoring systems with heritage of almost 80 YEARS of innovative diabetes care products Our products are sold in more than 125 COUNTRIES and help approximately 10 MILLION PEOPLE WORLDWIDE EVERY DAY Approximately 1,700 employees with opera
Slide 10: Why is this Partnership Important to Ascensia?
Why is this Partnership Important to Ascensia? EVERSENSE IS AN EXCELLENT PRODUCT: Differentiated and high quality product portfolio – market leading accuracy EXCITED BY THE PIPELINE: 365-day sensor* with once a week calibration and additional innovative features EXPANSION INTO CGM IS CRITICAL STRATE
Slide 11: What Does Ascensia Bring to this Partnership?
What Does Ascensia Bring to this Partnership? Partnership is a top priority, company focused only on diabetes, lead story for our business Commitment to making material investment into commercialization and prioritizing resources to support CGM Mature global organization with strong operational and
Slide 12: Thank You
THANK YOU ASCENSIA Diabetes Care
Slide 13: Fran Kaufman, M.D. CMO
Fran Kaufman, M.D. CMO
Slide 14: Why is it so Important to Manage Glucose in the Time of COVID-19?
Why is it so Important to Manage Glucose in the Time of COVID-19? Higher Risk for COVID-19 in People with Diabetes and Worse Outcome if Not Appropriately Managed. How is Better Outcome Achieved? Telemedicine, CGM, Access to Medications, etc. • March – April • 1122 patients; 451 with diabetes • Death
Slide 15: Telehealth Visits and the Role of CGM
Telehealth Visits and the Role of CGM For every 10% change in %TIR • AIC has been the driver of diabetes management for 3 decades 0.8% change in A1C • CGM is the new game changer • From CGM, obtain glucometrics • Calculate GMI, an estimation of the A1C • Can use Time in Range as long term outcome me
Slide 16: The Unique Features of Eversense
The Unique Features of Eversense Particular Advantages in Medicare Population Sensor Smart Transmitter Mobile App ▪ Glucose trends ▪ Fully implantable ▪ Powers sensor and calculates glucose ▪ Alerts and prompts ▪ Lasts up to: ▪ Placed on top of skin using silicone- based adhesive ▪ Data shared in re
Slide 17: Data in Support of Eversense
Data in Support of Eversense Particular Advantages in Medicare Population Real-World Data form U.S. Patients Using a Long-Term Implantable Continuous Glucose Sensor Presented at ADA 2020 Widespread Adoption of Age N of Median SG SD CV %GMI 70- <54 <70 >180 >250 CGM by payers wear mg/dL mg/dL 180 mg/
Slide 18: Evidence from an Independent Study - 180 Day System
Evidence from an Independent Study - 180 Day System Prospective, Multicenter, Independent Study of Health Outcomes in 100 Eversense Patients Using the 180 Day System All MDI CSII MDI CSII Patients CGM CGM Prior Prior Naïve Naïve CGM CGM • Significant reduction in A1C (34) (21) (10) (35) • Improvemen
Slide 19: Virtual Device Trainings
Virtual Device Trainings • Already Virtually Training Patients • Now Health Care Provider Training • ~400 HCPs certified and 200 in process • Here to Stay! Truly Scalable! Future Will Heavily Leverage Remote Tools Proven Effective During COVID
Slide 20: Data from CGM Gets Patient to Goal
Data from CGM Gets Patient to Goal Wear Time 92% TIR 72% Wear Time 94% TIR 84% 0.3% 0.9% 0.8% 6.3% 5.1% 7.0% 1.5% 3.6% 12.3% 23.7% 23.9% 20.8% 19.5% 28.5% 56.4% 36.9% 77.1% 90.6% 93.1% 90.1% 96.4% 76.1% 76.1% 77.7% 80.2% 71.2% 37.0% 49.5% 10.9% 5.7% 4.2% 1.3% 2.1% 1.5% 0.4% 4.2% 0.3% 12AM 4AM - 8AM
Slide 21: Summary
Summary • COVID-19 has shown us the promise of telemedicine and the value of CGM • CGM gives sufficient data during virtual visits to change treatment, address patient behaviors, and importantly improve outcomes • Eversense CGM has unique features, many of which resonate in the Medicare population •
Slide 22: Nick Tressler, CFO
Nick Tressler, CFO
Slide 23: Key Financial Targets (Preliminary Projections)
Key Financial Targets* (Preliminary Projections) Key Financial Targets* 2021E 2022E 2023E 2024E 2025E SENS Global Net Revenue $12M to $15M $30M to $40M $60M to $75M $100M to $120M $150M to $200M GM% -25% to -35% -10% to 0% 5% to 15% 35% to 45% 40% to 50% OpEx (Excludes COGS) $40M to $45M $45M to $55
Slide 24: Appendix A – Key Assumptions for Financial Targets
Appendix A – Key Assumptions for Financial Targets Overall • Ranges of Financial Targets are based on the Ascensia deal model as reviewed and approved by the Senseonics Board of Directors. • Revenue for Senseonics is assumed to be recognized in the period the product is shipped based on the appropri